Feb 24, 2026 05:47AM Vir Biotechnology (VIR) PT Raised to $18 at Evercore ISI

Feb 23, 2026 05:25PM Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 23c

Feb 23, 2026 05:15PM Vir Biotechnology announces collaboration with Astellas for VIR-5500

Feb 23, 2026 05:01PM Astellas partners with Vir Biotechnology on prostate cancer treatment

Jan 12, 2026 08:07AM Vir Biotechnology reports positive hepatitis delta trial data

Dec 30, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)

Dec 17, 2025 07:04AM Needham: 'VIR Strikes an ex-U.S. Deal for the HDV Program; Extends Cash Runway to 4Q27'

Dec 16, 2025 04:06PM Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment

Dec 9, 2025 04:24AM Leerink Partners: 'MIRM’s Bluejay Deal Nice External Recognition of HDV Value; Positive for VIR'

Nov 5, 2025 04:20PM Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 33c, provides guidance

Oct 7, 2025 08:04AM VIR to present hepatitis delta trial results at liver meeting

Sep 16, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)

Sep 3, 2025 05:15AM Evercore ISI Starts Vir Biotechnology (VIR) at Outperform, PT $12

Aug 27, 2025 06:09AM BofA Securities Upgrades Vir Biotechnology (VIR) to Buy, 'Underappreciated HDV opportunity, TCEs essentially free'

Aug 6, 2025 04:10PM Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance

Aug 6, 2025 08:06AM Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial

Jul 31, 2025 08:06AM Vir Biotechnology enrolls first patient in ECLIPSE 2 hepatitis delta trial

May 20, 2025 06:38AM Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright

May 7, 2025 04:13PM Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c

Mar 13, 2025 10:06AM Morgan Stanley Reiterates Overweight Rating on Vir Biotechnology (VIR)

Feb 26, 2025 04:14PM Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c

Jan 30, 2025 07:54AM Vir Biotechnology Inc. (VIR) Announces CTO Departure

Jan 9, 2025 04:25AM Morgan Stanley Upgrades Vir Biotechnology (VIR) to Overweight

Jan 8, 2025 04:01PM Goldman Sachs Reiterates Buy Rating on Vir Biotechnology (VIR)

Jan 8, 2025 01:27PM Vir Biotechnology (VIR) PT Raised to $14 at JPMorgan

Jan 8, 2025 11:18AM Increasing unusual call option volume: VIR OPTT ABSI QSI RGTI INVZ ALTM CRNC EBAY CALM BRCC OZK FUBO QUBT QBTS

Jan 8, 2025 07:46AM Vir Biotechnology Inc. (VIR) Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Jan 8, 2025 07:46AM Vir Biotechnology Inc. (VIR) Climbs After Releasing Slides Ahead of Investor Call

Dec 12, 2024 04:07PM Vir Biotechnology (VIR) Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 2, 2024 04:41PM Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)

Nov 20, 2024 07:51AM TD Cowen Reiterates Buy Rating on Vir Biotechnology (VIR)

Nov 18, 2024 04:06PM Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024 11:00AM Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations

Oct 31, 2024 04:10PM Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c

Oct 15, 2024 08:16AM Vir Biotechnology (VIR) Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs

Sep 10, 2024 08:05AM Vir Biotechnology (VIR) Appoints Jason O’Byrne as CFO

Sep 9, 2024 04:39PM After-hours movers: Oracle, Rubrik, Relay Therapeutics

Sep 9, 2024 04:13PM Vir Biotechnology (VIR) Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Aug 20, 2024 06:45AM H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)

Aug 1, 2024 04:24PM Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 13c ; Provides outlook

Aug 1, 2024 04:14PM Vir Biotechnology Inc. (VIR) Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cel

Aug 1, 2024 04:00PM Vir Biotechnology Inc. (VIR) Halted, News Pending

Jun 26, 2024 08:05AM Vir Biotechnology (VIR) Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection